pharmaphorum September 19, 2025
Biogen has reached a deal to buy Alcyone Therapeutics, a privately held company that has developed a system for delivering antisense oligonucleotides (ASOs) directly into the central nervous system.
The deal – which includes an upfront payment of $85 million – could accelerate Biogen’s efforts to develop a new formulation of its antisense therapeutic Spinraza (nusinersen) for spinal muscular atrophy (SMA), which is still bringing in blockbuster revenues, but has been declining in the face of increased competition from rival SMA therapies, including Roche’s orally-delivered Evrysdi (risdiplam) and Novartis’ one-shot gene therapy Zolgensma (onasemnogene abeparvovec).
Alcyone’s technology platform, ThecaFlex DRx, is an implantable intrathecal catheter, catheter fixation device, and subcutaneous port system designed to provide access to the cerebrospinal fluid...
Today's Sponsors
Today's Sponsor